SCHEMBL1497072

SCHEMBL1497072

Cc1cccc(CCNC(=O)N(CCN(C)C)Cc2ccc(C(=O)Nc3cscc3N)nc2)c1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDCD1 Q15116 6/20 0.38
CD274 Q9NZQ7 6/20 0.38
CNR1 P21554 1/20 0.36
HDAC1 Q13547 4/20 0.36
ROCK1 Q13464 2/20 0.36
HTR5A P47898 1/20 0.36
HDAC3 O15379 3/20 0.36
HDAC2 Q92769 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
RAF1 P04049 1/20 0.35
TP53 P04637 2/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HIF1A Q16665 1/20 0.35
IDO1 P14902 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1497058 0.92 HIF1A (0.44) PDCD1CD274CNR1HDAC1ROCK1
SCHEMBL12831708 0.92 PDCD1 (0.37) PDCD1CD274HDAC1ROCK1HTR5A
SCHEMBL1483172 0.91 HIF1A (0.42) PDCD1CD274HDAC1ROCK1HTR5A
SCHEMBL1496893 0.88 POLB (0.37) PDCD1CD274CNR1HDAC1ROCK1
SCHEMBL1497014 0.87 HIF1A (0.48) HDAC1ROCK1HTR5AHDAC3HDAC2
SCHEMBL1496888 0.87 ROCK1 (0.40) PDCD1CD274CNR1HDAC1ROCK1
SCHEMBL1496974 0.87 MEN1 (0.43) PDCD1CD274HDAC1ROCK1HDAC3
SCHEMBL8004129 0.87 ROCK2 (0.40) PDCD1CD274HDAC1ROCK1HTR5A
SCHEMBL8001271 0.86 HIF1A (0.41) PDCD1CD274HDAC1ROCK1HTR5A
SCHEMBL8004725 0.86 PDCD1 (0.37) PDCD1CD274HDAC1ROCK1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288380-B2 Thiophenediamine derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-10-16 US disclosed
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 US disclosed
EP-2292611-B1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2012-07-25 EP disclosed
US-8198271-B2 Thiophenediamine derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-06-12 US disclosed
US-20110077244-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-03-31 US disclosed
EP-2292611-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2011-03-09 EP disclosed
EP-2292611-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2011-03-09 EP disclosed
WO-2009142321-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE 参天製薬株式会社 (JP) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE CBR1, NAT1, PRMT1 PDCD1 4160/4885CD274 4096/4885CNR1 16/4885
US-20110077244-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE HNMT, HRH4, CHRM1 PDCD1 4547/4885CD274 4718/4885CNR1 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.